We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recombinant allergens for diagnosis of type 1 allergy.
- Authors
Mothes N; Valenta R; Spitzauer S; Renz H
- Abstract
Currently, diagnosis of type I allergy is performed using crude allergen extracts which allow the identification of the allergen-containing source responsible for type I allergic symptoms (e.g. allergic rhinoconjunctivitis, asthma) but not the disease-eliciting molecules. With the introduction of recombinant allergens by molecular biology techniques, a large panel of allergenic molecules has become available. The application of these recombinant allergens for in vitro tests leads to new forms of component-resolved diagnosis (CRD) and allows the establishment of a patient's individual reactivity profile. The increasing number of characterized recombinant allergens during the last decade has allowed developing chip-based allergy tests which enable the simultaneous detection of up to 5.000 different allergens and epitopes.The introduction of these recombinant allergen-based tests into clinical practice, on the one hand, improves the selection of patients for traditional specific immunotherapy and, on the other hand, enables the monitoring of the immunological efficacy of specific immunotherapy by measuring allergen-specific IgG antibodies.Besides their diagnostic application, recombinant allergens as well as hypoallergenic derivatives thereof have also been used as vaccines in clinical trials, and recent results have shown their usefulness for the treatment of type I allergy.
- Publication
Journal of Laboratory Medicine / Laboratoriums Medizin, 2005, Vol 29, Issue 4, p263
- ISSN
0342-3026
- Publication type
Journal Article